58 results about "Nci h460" patented technology

The invention discloses dibenzonaphthyridinone compounds represented by the formula (I), which is shown in the description. In the formula (I), R1a is independently chosen from -H and -CH3O, R1b is -CH3O; when R2a is -Cl, R2b and R2c are both -H; when R2b is -Cl, R2a and R2b are both -H; when R2c is independently chosen from -F, -Cl, -Br, -CH3, -CH3O, and -CF3, R2a and R2b are both -H; and R3 is (CH2)2N(CH3)2 or (CH2)3N(CH3)2. The invention further discloses a preparation method of dibenzonaphthyridinone compounds and an application of dibenzonaphthyridinone compounds in the preparation of anti-tumor drugs. The test results show that dibenzonaphthyridinone compounds have a good effect on inhibiting the activity of cells such as human stomach cancer cell (MGC-803), human lung cancer cell (NCI-H460), human liver cancer cell (HepG-2), human liver cancer cell (BEL-7404), and the like, and thus has a good application prospect in antitumor industry.

The invention discloses an acridine-1,2,4-triazole-5-thioketone compound and a preparation method and applications of the acridine-1,2,4-triazole-5-thioketone compound. The preparation method of the compound comprises the following steps: 1) by taking an o-bromobenzoic acid and p-methoxyaniline as raw materials, taking potassium carbonate and copper powder as catalysts, and taking isopentyl alcohol or n-amyl alcohol as a solvent, reacting so as to obtain a compound 1; 2) carrying out cyclization on the compound 1 by using phosphorus oxychloride so as to obtain a compound 2; 3) after the compound 2 is dissolved by using an organic solvent, in the presence of tetrabutylammonium bromide, reacting the dissolved compound 2 with sodium sulfocyanate so as to obtain a compound 3; 4) after the compound 3 is dissolved by using an organic solvent, reacting the dissolved compound 3 with m-nitrobenzoylhydrazine so as to obtain a compound 4; and 5) reacting the compound 4 with sodium carbonate, carrying out suction filtration on a reactant, collecting filter liquor, adjusting the pH value of the filter liquor to be less than 4, separating out precipitates, and carrying out suction filtration on the precipitates. In-vitro antitumor test results show that the compound has a significant in-vitro antitumor activity to tested MGC80-3, NCI-H460 and T24.

The invention discloses application of Lycojaponicumin A in preparation of medicaments for treating lung cancer. The compound shows good anti-lung cancer activity, can be used for preparing anti-lung cancer medicaments, and belongs to the technical field of new application of medicaments. The Lycojaponicumin A can prominently inhibit non-small cell lung cancer cells A549, large cell lung cancer cells NCI-H460, lung squamous cancer cells HTB-8 and human lung flat epithelial cancer cells QG-5 cultured in vitro, has a low inhibiting effect on human normal liver cells LO2 and peripheral blood lymphocytes, and shows obvious selectivity. The application of the Lycojaponicumin A in preparation of the medicaments for treating the lung cancer is made public for the first time; and because the skeleton type is completely novel, the Lycojaponicumin A has an unexpectedly strong lung cancer cell inhibiting activity.